EP3725810
SAMSETT MEÐFERÐ SEM FELUR Í SÉR MÓTEFNI GEGN CLAUDIN 18.2 TIL MEÐFERÐAR VIÐ KRABBAMEINI
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
21.5.2013EP published:
6.7.2022EP application number:
20163993.7
EP translation filed:
25.7.2022Grant published:
15.8.2022EPO information:
European Patent Register
Max expiry date:
20.5.2033Expiry date:
20.5.2025
Title in English:
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCERLanguage of the patent:
English
Timeline
Today
21.5.2013EP application
6.7.2022EP Publication
25.7.2022Translation submitted
15.8.2022Registration published
20.5.2025Expires
Owner
Name:
Astellas Pharma Inc.Address:
5-1, Nihonbashi-honcho 2-chome, Chuo-ku Tokyo 103-8411, JP
Name:
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbHAddress:
Freiligrathstrasse 12, 55131 Mainz, DE
Inventor
Name:
SAHIN, UgurAddress:
55116 Mainz, DE
Name:
TÜRECI, ÖzlemAddress:
55116 Mainz, DE
Name:
MITNACHT-KRAUS, RitaAddress:
61169 Friedberg, DE
Name:
JACOBS, Stefan DenisAddress:
55252 Mainz-Kastel, DE
Name:
UTSCH, Magdalena JadwigaAddress:
55262 Heidesheim am Rhein, DE
Name:
HEINZ, Cornelia Adriana MariaAddress:
55278 Dalheim, DE
Name:
STADLER, Christiane ReginaAddress:
64625 Bensheim, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/EP2012/002211Date:
23.5.2012Country:
WO
Classification
Categories:
C07K 16/30, A61K 39/395, A61K 45/06, A61K 31/513, A61K 31/519, A61K 31/555, A61K 31/675, A61K 31/704, A61K 31/7068, A61K 33/243, A61K 39/00, A61P 35/00, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 23.5.2023
Expires: 20.5.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 2.5.2024
Expires: 20.5.2025
Payer: Árnason Faktor ehf.